Microangiopathic hemolytic anemia: Difference between revisions

No edit summary
Line 12: Line 12:
*Drugs: chemotherapy; [[Clopidogrel]] (Plavix) associated with [[TTP]]
*Drugs: chemotherapy; [[Clopidogrel]] (Plavix) associated with [[TTP]]
*Nonvascular causes: prosthetic valve (more common w/ mechanical, more common at aortic valve), [[LVAD]], [[TIPS]], coil embolization, patched AV shunt, [[AVM]]
*Nonvascular causes: prosthetic valve (more common w/ mechanical, more common at aortic valve), [[LVAD]], [[TIPS]], coil embolization, patched AV shunt, [[AVM]]
{{Hemolytic anemia DDX}}


==Work-Up==
==Work-Up==

Revision as of 13:05, 29 June 2015

Background

Microangiopathic hemolytic anemia (MAHA) = variety of conditions that result in damaged endothelium of small vessels causing platelet aggregation and fibrin deposition which leads to shearing forces within these small vessels causing an intravascular fragmentation hemolysis

Diagnosis

  • Clinical features + heme labs with red blood cell fragments or schistocytes.[1]
  • May have bleeding and thrombosis

Differential Diagnosis

Microangiopathic Hemolytic Anemia (MAHA)

Work-Up

  • Peripheral smear, hemoglobin, platelets, PT/INR, PTT, fibrinogen, FDPs, D-dimer, haptoglobin, LDH, bilirubin
    • Schistocytes (aka Helmet cells) secondary to fragmentation hemolysis classic finding on peripheral smear

Lab Findings

  • Schistocytes
  • High: +/- LDH and unconjugated bilirubin
  • Low: Hgb, platelets, +/- haptoglobin

General Rules

  • DIC= elevated PT/INR/PTT/FDPs/D-dimer, low fibrinogen[1]
  • TTP/HUS = normal PT/INR/PTT/FDPs/D-dimer/fibrinogen[1]

Management

See Also

Sources

  1. 1.0 1.1 1.2 Scully. Marie et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35. PDF